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Marine organisms are rich in a variety of materials with potential use in Tissue Engineering and 
Regenerative Medicine. One important example is fucoidan, a sulfated polysaccharide extracted from 
the cell wall of brown seaweeds.  Fucoidan is composed by L-fucose, sulfate groups and glucuronic acid. 
It has important bioactive properties such as anti-oxidative, anticoagulant, anticancer and reducing the 
blood glucose (1). In this work, the biomedical potential of fucoidan-based materials as drug delivery 
system was assessed by processing modified fucoidan (MFu) into particles by photocrosslinking using 
superamphiphobic surfaces and visible light. Fucoidan was modified by methacrylation reaction using 
different concentrations of methacrylate anhydride, namely 8% v/v (MFu1) and 12% v/v (MFu2). 
Further, MFu particles with and without insulin (5% w/v) were produced by pipetting a solution of 5% 
MFu with triethanolamine and eosin-y onto a superamphiphobic surface and then photocrosslinking 
using visible light (2). The developed particles were characterized to assess their chemistry, morphology, 
swelling behavior, drug release, insulin content and encapsulation efficiency. Moreover, the viability 
assays of fibroblast L929 cells in contact with MFu particles showed good adhesion and proliferation up 
to 14 days. Furthermore, the therapeutic potential of these particles using human beta cells is currently 
under investigation. Results obtained so far suggest that modified fucoidan particles could be a good 
candidate for diabetes mellitus therapeutic approaches. 
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